The anti-cancer activity of noscapine: A review

Recent Patents on Anti-Cancer Drug Discovery

Volumn 4, Issue 1, 2009, Pages 92-97

  Mahmoudian, Massoud ^a   Rahimi Moghaddam, Parvaneh ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti cancer; Anti mitotic; Antitussive; Apoptosis; Noscapine

Indexed keywords

5 BROMONOSCAPINE; 9 CHLORONOSCAPINE; ANTISENSE OLIGONUCLEOTIDE; COLCHICINE; DEXTROMETHORPHAN; DOCETAXEL; EM 015; NOSCAPINE; PACLITAXEL; PODOPHYLLOTOXIN; PROTEIN BCL 2; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VINCA ALKALOID; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW TOXICITY; BREAST CANCER; CARDIOTOXICITY; COLON CANCER; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; DUODENUM DISEASE; GLIOBLASTOMA; HUMAN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MUTAGENICITY; NEPHROTOXICITY; NONHUMAN; OVARY CARCINOMA; PATENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SMALL INTESTINE DISEASE; SPLEEN DISEASE; STRUCTURE ANALYSIS; UNSPECIFIED SIDE EFFECT; ANIMAL; DRUG EFFECT; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; NEOPLASMS; NOSCAPINE;

EID: 62749139595     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489209787002524     Document Type: Review

References (51)

1. Segal MS, Goldstein MM, Attinger EO. The use of noscapine (narcotine) as an antitussive agent. Dis Chest 1957; 32: 305-309.
2. Empey DW, Laitinen LA, Young GA, Bye CE, Hughes DTD. Comparison of the antitussive effects of codeine phosphate 20mg dextromethorphan 30mg and noscapine 30mg using citric acid-induced cough in normal subjects. Eur J Clin Pharmacol 1979; 16: 393-397.
3. Dahlstrom B, Mellstrand T, Lofdahl CG, Johansson M. Pharmakokinetic Properties of Noscapine. Eur J Clin Pharmacol 1982; 22: 535-539.
4. Karlsson MO, Dahlstrom B, Eckernas SA, Johansson M, Tufvesson-Alm A. Pharmacokinetics of oral noscapine. Eur J Clin Pharmacol 1990; 39: 275-279.
5. Mooraki A, Jenabi A, Jabbari M, et al. Noscapine suppresses ACE-induced cough. Nephrol 2005; 10: 348-350.
6. Ebrahini SA, Zareie, Rostami, P, Mahmoudian M. Interaction of noscapine with the bradykinin mediation of the cough response. Acta Physiol Hun 2003; 90: 147-155.
7. Mahmoudian M. Recent progress in clinical application of noscapine: a review. Cur Topics Pharmacol 2006; 10: 81-86.
8. Mobasheri T, Rostami P, Khodakarami P. Noscapine anxiolytic effects in mice. Al-Zahra University J Sci 2002; 15: 25-32.
9. Winter CA, Flataker L. Toxocity studies on noscapine. Toxicol App Pharmacol 1961; 3: 96-106.
10. Lasagna L, Owens Jr AH, Shnider BI, Gold L. Toxicity after large doses of noscapine. Cancer Chemother Rep 1961; 15: 33-34.
11. Johansson M, Tufvesson-Alm A, forsmo-Bruce H, Jacpbsson S, Westerlund D. Determination of noscapine and its metabolites in plasma using coupled liquid chromatography. J Chromatogr 1988; 459: 301-311.
12. Chollet DF, Ruols C, Arnera V. Determination of noscapine in human plasma using solid-phase extraction and high-performace liquid chromatography. J Liquid Chromatogr B 1997; 701: 81-85.
13. Aneja R, Dhiman N, Idnani J, et al. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding agent. Cancer Chemother Pharmacol 2007; 60: 831-839.
14. Idanpaan-Heikkila JF. An autoradiographic study on rhe distribution of 3H-noscapine in mice. Eur J Pharmacol 1967; 2: 26-34.
15. Craviso, GL, Musacchio JM. High-affinity dextromethorphan binding sites in guinea-pig brain. I. Initial characterization. Mol Pharmacol 1983; 23: 619-628.
16. Craviso GL, and Musacchio JM. High-affinity Dextromethorphan binding sites in guinea-pig brain. II. Competition experiments. Mol Pharmacol 1983; 23: 629-640.
17. Musaccio JM, Klein M, Santiago LJ. Allosteric modulation of dextromethorphan binding sites. Neuropharmacol 1987; 26: 997-1001.
18. 3H] noscapine in guinea pig brain tissue. Eur J Pharmacol 1988; 145: 195-203.
19. Karlsson, MO, Neil A. Estimation of binding parameters by kinetic data analysis: Differentiation between one and two binding sites. Eur J Pharmacol 1988; 148: 115-121.
20. Mourey RJ, Dawson TM, Barrow RK, Enna AE, Snyder SH. 3HNoscapine binding sites in brain: Relationship to Indoleamines and the phosphoinositide and adenylyl cyclase messenger system. Mol Pharmacol 1992; 42:619-626.
21. Ye K, Ke Y, Keshava N, et al. Opium alkaloid noscapine is an antitumor agent that arrest metaphase and induces apoptosis in dividing cells. Proc Natl Acad Sci USA 1998; 95: 1601-1606.
22. Yong K, Ye K, Grossniklanus HE, Archer DR, Joshi HC, Kapp JA. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. Cancer Immunol Immunother 2000; 49: 217-225.
23. Joshi HC, Zhou J. Noscapine and analogues as potential Chemotherapeutic agents. Drug News Perspect 2000; 13: 543-546.
24. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 305-327.
25. Kavallaris M, Burkhart CA, Horwitz SB. Antisense oliginucleotides to class III beta-tubulin sensitizes drug-resistant cells to taxol. Br J Cancer 1999; 80: 1020-1025.
26. Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997; 272: 17118-17125.
27. Verma AK, Bansai S, Singh J, et al. Synthesis and in vitro cytotoxicity of haloderivatives of noscapine. Med Chem 2006; 14: 6733-6736.
28. Zhou J, Gupta K, Yao J, et al. Paclitaxel-resistant human ovarian cancer cells undergo c-jun NH2-terminal kinase-mediated apoptosis in response to noscapine. J Biol Chem 2002; 277: 39777-39785.
29. Ke Y, Ye K, Grossniklaus HE, et al. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. Cancer Immunol Immunother 2000; 49: 217-225.
30. Aneja R, Vangapandu SN, Lopus M, Chandra R, Panda D, Joshi HC. Development of a novel nitro-derivative of noscapine for the potential treatment of drug- resistant ovarian cancer and T-cell lymphoma. Mol Pharmacol 2006; 69:1801-1809.
31. Aneja R, Zhou J, Vangapandu SN, Zhou B, Chandra R, Joshi HC. Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011. Blood 2006; 107: 2486-2492.
32. Aneja R, Zhou J, Zhou B, Chandra R, Joshi HC. Treatment of hormone-refractory breast cancer: Apoptosis and regression of human tumors implanted in mice. Mol Cancer Ther 2006; 5: 2366-2377.
33. Aneja R, Lopus M, Zhou J, et al. Rational design of the microtubule-targeting anti-breast cancer drug EM015. Cancer Res 2006; 66: 3782-3791.
34. Landen JW, lang R, McMahon SJ, et al. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res 2002; 62: 4109-4114.
35. Zhou J, Gupta K, Aggarwal S, Aneja R, Panda R, Joshi HC. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation. Mol Pharmacol 2003; 63: 799-807.
36. Landen JW, Hau V, Wang M, et al. Noscapine Crosses the blood-brain and inhibits glioblastoma growth. Clin Cancer Res 2004; 10: 5187-5201.
37. Aneja R, Ghaleb AM, Zhou J, Yang VW, Joshi HC. P53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res 2007; 67: 3862-3870.
38. Jackson T, Chougule MB, Ichite N, Patlolla RR, Singh M. Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. Cancer Chemother Pharmacol 2008; 63: 117-126.
39. Rahbar-Roshandel N, Salehi S, Moghaeri B, Ebrahimi SA, Mahmoudian M. Noscapine enhances cisplatin-induced cytotoxicity and caspase-3 activation. IJPT 2008; Submitted.
40. Rahbar-Roshandel N, Shojaee SH, Motamen A, Mahmoudian M. Noscapine reverses doxorubicin and vincristine resistance in OVCAR3 cell line. IJPT 2008; Submitted.
41. Newcomb EW, Lukyanov Y, Alonso-Basanta M, et al. Antiangiogenic effects of noscapine enhance radioresponse for GL261 tumors. Int J Radiat Oncol Biol Phys 2008; 71: 1477-1484.
42. Heidari N, Goliaei B, Rahimi-Moghaddam P, Rahbar-Roshandel N, Mahmoudian M. Apoptotic Pathway induced by noscapine in human myelogenous leukemic cells. Anti-Cancer Drugs 2007; 28: 1139-1147.
43. Newcomb EW, Lukyanova Y, Simirnova I, Schnee T, Zagzag D. Noscapine induces apoptosis in human glioma cells by an AIF-dependent pathway. Anti-Cancer Drugs 2008; 19: 553-563.
44. Mitchell ID, Carlton JB, Chan MY, Robinson A, Sunderland J. Noscapine-induced polyploidy in vitro. Mutagenesis 1991; 6: 479-486.
45. Kirpnick Z, Homiski M, Rubitski E, et al. Yeast DEL assay detects clastogens. Mut Res 2005; 582: 116-134.
46. Aneja R, Vangapandu SN, Joshi HC. Synthesis and biological evaluation of a cyclic ether fluorinated noscapine analog. Bioorag Med Chem 2006; 14: 8352-8358.
47. Aneja R, Vangapandu SN, Lopus M, et al. Synthesis of microtubule-interfering halogenated noscapine analogs that perturb mitosis in cancer cells followed by cell death. Biochem Pharmacol 2006; 72: 415-426.
48. Kim, T. S., Bellon, S., Booker, S., D'angelo, N., Dominguez, C., Fellows, I., Lee, M., Liu, L., Rainbeau, E., Siegmund, A. C., Tasker, A., Ning, X., Cheng, Y.: WO2006060318 (2006).
49. Welsh, W. J., Yu, S. J., Nair, A.: US20070105884 (2007).
50. Chang, D.: WO2006102504 (2006).
51. Kapp, J., Ke, Y.: US20067090853 (2006).